(Q41334078)

29 September 2017

title

T cell-targeted immunofusion proteins from Escherichia coli (English)

1 reference

29 September 2017

Escherichia coli

1 reference

Better M

1 reference

29 September 2017

Bernhard SL

1 reference

29 September 2017

Williams RE

1 reference

29 September 2017

Leigh SD

1 reference

29 September 2017

Bauer RJ

1 reference

29 September 2017

Kung AH

1 reference

29 September 2017

Carroll SF

1 reference

29 September 2017

Fishwild DM

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 June 1995

1 reference

Journal of Biological Chemistry

29 September 2017

published in

1 reference

29 September 2017

volume

270

1 reference

29 September 2017

1 reference

29 September 2017

page(s)

14951-14957

1 reference

Recombinant Toxins for Cancer Treatment

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Affinity purification and characterization of anti-Tac(Fv)-C3-PE38KDEL: A highly potent cytotoxic agent specific to cells bearing IL-2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Expression of engineered antibodies and antibody fragments in microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

LIGAND: A versatile computerized approach for characterization of ligand-binding systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Production and secretion of a bifunctional staphylococcal protein A::antiphytochrome single-chain Fv fusion protein in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

Efficacy of anti-CD5 F(ab')2 and Fab' immunoconjugates in human peripheral blood lymphocyte-reconstituted severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.270.25.14951

21 January 2018

Identifiers

DOI

10.1074/JBC.270.25.14951

1 reference

29 September 2017

1 reference